Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib
Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib
About this item
Full title
Author / Creator
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Proteasome inhibitors disrupt multiple pathways in cells and the bone marrow microenvironment, resulting in apoptosis and inhibition of cell-cycle progression, angiogenesis, and proliferation. Bortezomib is a first-in-class proteasome inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma after one prior therapy. It is al...
Alternative Titles
Full title
Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2045269745
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2045269745
Other Identifiers
ISSN
0312-5963
E-ISSN
1179-1926
DOI
10.1007/s40262-018-0679-9
